Pirfenidone
Brand names: Esbriet
Pirfenidone is an oral antifibrotic agent used to treat idiopathic pulmonary fibrosis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It has antifibrotic and anti-inflammatory actions, attenuating fibroblast proliferation and the production of fibrosis-associated mediators and collagen, although its precise mechanism is not fully defined.
Prescribing in practice
- Photosensitivity and rash are common, so strict sun protection and avoidance of strong sunlight are essential.
- Hepatotoxicity can occur, requiring liver function testing before and during treatment with dose adjustment for derangement.
- Gastrointestinal upset is common; taking doses with food improves tolerability, and smoking can reduce drug exposure.
Monitoring
Check liver function before starting and periodically during treatment, and monitor for skin reactions, gastrointestinal effects and weight loss.
Counselling the patient
- Use high-factor sun cream, cover up and avoid sunbeds while taking this medicine.
- Take the capsules with food to reduce nausea and report yellowing of the skin or eyes.
- Tell your doctor if you smoke, as it can affect how this medicine works.
Evidence & guidelines
The ASCEND and CAPACITY trials showed that pirfenidone slows lung function decline in idiopathic pulmonary fibrosis, supporting NICE-recommended use.
Reference: ASCEND Trial (King et al, NEJM 2014); NICE TA379; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024